Nilotinib

From WikiMD.org
Jump to navigation Jump to search

Nilotinib

Nilotinib (pronounced: nil-oh-TIN-ib) is a type of tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia (CML). It is marketed under the brand name Tasigna by Novartis.

Etymology

The name "Nilotinib" is derived from the chemical name Nilo-tin-ib, where "-ib" is a suffix used in drugs that are tyrosine kinase inhibitors.

Usage

Nilotinib is used to treat chronic myelogenous leukemia (CML), a type of cancer that starts in the blood-forming cells of the bone marrow. It is specifically used in cases where the disease is in the chronic phase, and the patient has not responded to or cannot tolerate other treatments, such as imatinib.

Mechanism of Action

Nilotinib works by blocking certain proteins that signal cancer cells to divide and grow. It binds to and inhibits the protein BCR-ABL, which is found in CML cells. This helps to stop or slow the spread of cancer cells.

Side Effects

Common side effects of Nilotinib include nausea, rash, itching, headache, fatigue, and diarrhea. Serious side effects can include liver damage, pancreatitis, and heart problems.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski